TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
TAMPA, Fla., Nov. 13, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's third quarter...
Covered in this story
Call it yourself
No calls on $HURA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Tuhura Biosciences Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.